Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

As we enter the 2000's it is clear that cytokine blockade is an effective therapeutic strategy for rheumatoid arthritis. In this brief review, we will review the rationale for anti TNFalpha therapy, the current status of therapy and focus on the regulation of TNFalpha production in rheumatoid synovium. New approaches to studying TNF regulation in RA and of elucidating the controversial role of T cells in this complex disease will be described.


Journal article


Adv Exp Med Biol

Publication Date





119 - 127


Adenoviridae, Arthritis, Rheumatoid, Cytokines, DNA-Binding Proteins, Humans, I-kappa B Proteins, Interleukin-1, NF-KappaB Inhibitor alpha, NF-kappa B, T-Lymphocytes, Tumor Necrosis Factor-alpha